- Home
- OPT vs SPTN Comparison
OPT vs SPTN Comparison
Compare OPT & SPTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPT
- SPTN
- Stock Information
- Founded
- OPT 1984
- SPTN 1917
- Country
- OPT Australia
- SPTN United States
- Employees
- OPT N/A
- SPTN N/A
- Industry
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- SPTN Food Distributors
- Sector
- OPT Health Care
- SPTN Consumer Discretionary
- Exchange
- OPT Nasdaq
- SPTN Nasdaq
- Market Cap
- OPT 855.6M
- SPTN 686.2M
- IPO Year
- OPT 2020
- SPTN N/A
- Fundamental
- Price
- OPT $5.09
- SPTN $19.67
- Analyst Decision
- OPT Strong Buy
- SPTN Hold
- Analyst Count
- OPT 1
- SPTN 1
- Target Price
- OPT $12.00
- SPTN $20.00
- AVG Volume (30 Days)
- OPT 40.1K
- SPTN 290.2K
- Earning Date
- OPT 03-03-2025
- SPTN 02-12-2025
- Dividend Yield
- OPT N/A
- SPTN 4.42%
- EPS Growth
- OPT N/A
- SPTN N/A
- EPS
- OPT N/A
- SPTN 0.01
- Revenue
- OPT $261,859.00
- SPTN $9,549,324,000.00
- Revenue This Year
- OPT N/A
- SPTN $4.01
- Revenue Next Year
- OPT $46,864.26
- SPTN $0.37
- P/E Ratio
- OPT N/A
- SPTN $2,220.41
- Revenue Growth
- OPT N/A
- SPTN N/A
- 52 Week Low
- OPT $1.79
- SPTN $17.30
- 52 Week High
- OPT $6.30
- SPTN $23.00
- Technical
- Relative Strength Index (RSI)
- OPT 53.99
- SPTN 56.82
- Support Level
- OPT $4.77
- SPTN $18.78
- Resistance Level
- OPT $5.46
- SPTN $21.23
- Average True Range (ATR)
- OPT 0.32
- SPTN 0.65
- MACD
- OPT -0.11
- SPTN 0.07
- Stochastic Oscillator
- OPT 20.60
- SPTN 54.91
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.
About SPTN SpartanNash Company
SpartanNash Co is a food solutions company that delivers the ingredients. Its principal business activities include, distributing grocery products to a diverse group of independent and chain retailers, its corporate-owned retail stores, and U.S. military commissaries and exchanges; as well as operating a fresh produce distribution network and the Our Family private label brand. The company operates in two segments: Retail and Wholesale. Majority of the revenue is earned from its Wholesale segment which uses a multi-channel sales approach to distribute national brand and private brand products to independent retailers, national accounts, food service distributors, e-commerce providers, and the Company's corporate owned retail stores.